siRNA

Title: RNA Interference Modulators of Hedgehog Signaling and Uses Thereof
Patent Number: 8,802,639
Filed: March 24, 2005

NEW YORK (GenomeWeb) – InteRNA Technologies and academic collaborators this month reported details of an siRNA-delivery technology capable of specifically targeting tumor vasculature, along with in vitro data demonstrating its ability to carry siRNAs into human umbilical vein endothelial

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

This article has been updated to include information about Life Technologies' spokesperson.

Looking to harness the gene-silencing efficiency of siRNAs to enhance the potency of disease-targeting microRNAs, a team of researchers from Washington University has developed new molecules that incorporate features of both classes of small RNAs.